One-year outcomes of daratumumab-based vs. non-daratumumab regimens in AL amyloidosis: A propensity-matched real-world studyChidiebube Ugwu, Alankrita Taneja, Nneoma Ubah et al.|Blood|2025Cited by 0
SGLT2 inhibitors and outcomes in pancreatic cancer: A large-scale propensity-matched cohort study.Chidiebube J. Ugwu, Alankrita Taneja, Colton Jones et al.|Journal of Clinical Oncology|2026Cited by 0
Abstract 3994: Differences in the mutational landscape across race and sex highlight distinct TP53-associated risk in multiple myelomaChidiebube Ugwu, Amin Turki, Nneoma Ubah et al.|Cancer Research|2026Cited by 0
Timing of Tyrosine Kinase Inhibitor Switching in Chronic Myeloid Leukemia: A Comparative Analysis of Early Versus Late StrategiesChidiebube J. Ugwu, Alankrita Taneja, Tarfa Verinumbe et al.|Clinical Lymphoma Myeloma & Leukemia|2026Cited by 0